|
1）Sekijima Y, Yoshida K, Tokuda T, et al. Familial Transthyretin Amyloidosis (January 2012) in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online] Copyright, University of Washington, Seattle 1993-2014 Available at http://www.ncbi.nlm.nih.gov/books/NBK1194/
|
|
|
|
|
2）Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 8: 31
|
|
|
|
|
3）Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver-transplantation in hereditary transthyretin amyloidosis. Lancet. 1993; 341: 1113-6
|
|
|
|
|
4）Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med. 2005; 352: 2356
|
|
|
|
|
|
5）Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005; 121: 73-85
|
|
|
|
|
|
6）関島良樹，池田修一．家族性アミロイドポリニューロパチー．医学のあゆみ．2013; 247: 515-20
|
|
|
|
|
7）Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013; 310: 2658-67
|
|
|
|
|
|
8）Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012; 79: 785-92
|
|
|
|
|
|
9）Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013; 369: 819-29
|
|
|
|
|
|
10）Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid. 2012; 19 Suppl 1: 43-4
|
|
|
|
|
|
11）Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014; 39: 225-33
|
|
|
|
|
|
12）Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991; 40: 242-6
|
|
|
|
|
|
13）山下太郎．家族性アミロイドポリニューロパチー 肝移植の現状．BRAIN and NERVE. 2014; 66: 763-71
|
|
|
|
|
|
14）Wilczek HE, Larsson M, Ericzon BG. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid. 2011; 18 Suppl 1: 193-5
|
|
|
|
|
|
15）Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012; 78: 637-43
|
|
|
|
|
|
16）Okamoto S, Wixner J, Obayashi K, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patientsʼ survival. Liver Transpl. 2009; 15: 1229-35
|
|
|
|
|
|
17）Okamoto S, Zhao Y, Lindqvist P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid. 2011; 18: 200-5
|
|
|
|
|
|
18）Ando Y, Terazaki H, Nakamura M, et al. A different amyloid formation mechanism: De novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation. 2004; 77: 345-9
|
|
|
|
|
|
19）Hammarstrom P, Sekijima Y, White JT, et al. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: A prescription for central nervous system amyloidosis? Biochemistry (Mosc). 2003; 42: 6656-63
|
|
|
|
|
|
20）Sekijima Y, Hammarstrom P, Matsumura M, et al. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest. 2003; 83: 409-17
|
|
|
|
|
|
21）Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun. 2000; 274: 702-6
|
|
|
|
|
|
22）Dubrey SW, Davidoff R, Skinner M, et al. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation. 1997; 64: 74-80
|
|
|
|
|
|
23）Hammarstrom P, Jiang X, Hurshman AR, et al. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A. 2002; 99: 16427-32
|
|
|
|
|
|
24）Hammarstrom P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001; 293: 2459-62
|
|
|
|
|
|
25）Miroy GJ, Lai ZH, Lashuel HA, et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A. 1996; 93: 15051-6
|
|
|
|
|
|
26）Hammarstrom P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003; 299: 713-6
|
|
|
|
|
|
27）Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004; 84: 545-52
|
|
|
|
|
|
28）Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006; 13: 236-49
|
|
|
|
|
|
29）Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012; 109: 9629-34
|
|
|
|
|
|
30）Coelho T, Maia L, Martins da Silva A, et al. Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid. Amyloid. 2010; 17 Suppl 1: 75-6
|
|
|
|
|
|
31）Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013; 260: 2802-14
|
|
|
|
|
|
32）Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 2010; 107: 1864-9
|
|
|
|
|
|
33）Alvarez R, Borland T, Chen Q, et al. ALN-TTR, an RNAi therapeutic for the treatment of transthyretinmediated amyloidosis. Amyloid. 2010; 17 Suppl 1: 51-2
|
|
|
|
|
|
34）Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006; 33: 609-18
|
|
|
|
|
|
35）Benson MD, Smith RA, Hung G, et al. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid. 2010; 17: 43-9
|
|
|
|
|
|
36）Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006; 20: 234-9
|
|
|
|
|
|
37）Macedo B, Batista AR, Ferreira N, et al. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta. 2008; 1782: 517-22
|
|
|
|
|
|
38）Cardoso I, Martins D, Ribeiro T, et al. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010; 8: 74
|
|
|
|
|
|
39）Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012; 19 Suppl 1: 34-6
|
|
|
|
|
|
40）Terazaki H, Ando Y, Fernandes R, et al. Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest. 2006; 86: 23-31
|
|
|
|
|
|
41）Su Y, Jono H, Torikai M, et al. Antibody therapy for familial amyloidotic polyneuropathy. Amyloid. 2012; 19 Suppl 1: 45-6
|
|
|
|
|